Wedbush Morgan downgrades Repros Therapeutics Inc. (Nasdaq: RPRX) from Buy to Hold and lowers their price target from $12 to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE